Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanylate cyclase-C (GC-C), also known as guanylyl cyclase C or GUCY2C, is a type I transmembrane receptor with intrinsic guanylate cyclase activity. It is predominantly expressed on the apical surface of intestinal epithelial cells. GC-C plays a central role in regulating intestinal fluid and electrolyte homeostasis, mucosal barrier function, and epithelial regeneration. It is a therapeutic target for conditions like chronic constipation and IBS-C, and also a biomarker and therapeutic target for colorectal cancer.
GC-C agonists bind to the extracellular domain, stimulating the intracellular catalytic domain to convert GTP to cGMP. cGMP activates downstream targets like PKG-II, leading to increased chloride and bicarbonate secretion and inhibition of sodium absorption, resulting in net water efflux into the intestinal lumen.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Guanylate Cyclase C (GC-C).